Literature DB >> 6614160

Vasoconstrictor-evoked prostaglandin synthesis in cultured vascular smooth muscle.

A Hassid, C Williams.   

Abstract

We investigated the hypothesis that vasopressin, angiotensin II, and norepinephrine stimulate the synthesis of vasodilatory prostaglandins in cultured vascular smooth muscle cells from rat mesenteric arteries. The major prostaglandin synthesized by subcultured vascular smooth muscle cells was PGI2 (measured as its stable metabolite 6-keto-PGF1 alpha) followed by 1/20th to 1/40th as much PGF2 alpha and PGE2. Vasopressin and angiotensin II dose dependently increased prostaglandin synthesis with a half-maximal stimulatory concentration of the order of 1 X 10(-8) M for both peptides. However, vasopressin could provoke the synthesis of two to three times as much PGI2 as angiotensin II, at maximally effective concentrations. Vasopressin's ability to provoke prostaglandin synthesis depended on its pressor activity as demonstrated by the ability of a potent antipressor analogue of vasopressin, [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid), 2-(O-methyl)tyrosine] arginine vasopressin, to completely inhibit vasopressin-provoked prostaglandin synthesis. Moreover, 1-desamino-8-D-arginine vasopressin, an analogue having full antidiuretic but no pressor activity was much less effective than vasopressin as a prostaglandin-stimulatory agent. Unlike peptide vasoconstrictors, norepinephrine (10(-9) to 10(-5) M) had no ability to stimulate prostaglandin synthesis in vascular smooth muscle cells. We conclude that the potent vasodilator PGI2, released from vascular smooth muscle cells, may buffer the peptide-induced vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6614160     DOI: 10.1152/ajpcell.1983.245.3.C278

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Effects of prostaglandin I2 synthesized in the endothelium and in the smooth muscle on mechanical properties of the canine thoracic aorta.

Authors:  M Domae; H Kuriyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

2.  Activation of V1-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets.

Authors:  W Siess; M Stifel; H Binder; P C Weber
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

3.  Biphasic forearm vascular responses to intraarterial arginine vasopressin.

Authors:  S Suzuki; A Takeshita; T Imaizumi; Y Hirooka; M Yoshida; S Ando; M Nakamura
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  Differential changes of adrenoceptor- and muscarinic receptor-linked prostacyclin synthesis by the aorta and urinary bladder of the diabetic rat.

Authors:  J Y Jeremy; C S Thompson; D P Mikhailidis
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Effect of vasoactive peptides on prostacyclin synthesis in man.

Authors:  S E Barrow; C T Dollery; D J Heavey; N E Hickling; J M Ritter; J Vial
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

6.  Evidence against the hypothesis that prostaglandins are the vasodepressor agents of pregnancy. Serial studies in chronically instrumented, conscious rats.

Authors:  K P Conrad; M C Colpoys
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

7.  Relaxation of human isolated mesenteric arteries by vasopressin and desmopressin.

Authors:  M C Martínez; J M Vila; M Aldasoro; P Medina; B Flor; S Lluch
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

8.  Effects of thromboxane synthase inhibition on vascular responsiveness in the in vivo rat mesentery.

Authors:  E K Jackson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

9.  The presence of Superfund sites as a determinant of life expectancy in the United States.

Authors:  Amin Kiaghadi; Hanadi S Rifai; Clint N Dawson
Journal:  Nat Commun       Date:  2021-04-13       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.